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Background: Tobacco smoking is known to be the single largest cause of premature death worldwide. The aim of
present study was to analyse the effect of smoking on general and cause-specific mortality in the Estonian population.
Methods: The data from 51,756 adults in the Estonian Genome Center of the University of Tartu was used. Information
on dates and causes of death was retrieved from the National Causes of Death Registry. Smoking status, general
survival, general mortality and cause-specific mortality were analysed using Kaplan-Meier estimator and Cox
proportional hazards models.
Results: The study found that smoking reduces median survival in men by 11.4 years and in women by 5.8 years.
Tobacco smoking produces a very specific pattern in the cause of deaths, significantly increasing the risks for different
cancers and cardiovascular diseases as causes of death for men and women. This study also identified that external
causes, such as alcohol intoxication and intentional self-harm, are more prevalent causes of death among smokers than
non-smokers. Additionally, smoking cessation was found to reverse the increased risks for premature mortality.
Conclusions: Tobacco smoking remains the major cause for losses of life inducing cancers and cardiovascular diseases.
In addition to the common diseases, external causes also reduce substantially the years of life. External causes of death
indicate that smoking has a long-term influence on the behaviour of smokers, provoking self-destructive behaviour.
Our study supports the idea, that tobacco smoking generates complex harm to our health increasing mortality from
both somatic and mental disorders.
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Tobacco smoking is a single major cause of premature
death worldwide [1, 2]. Despite substantial reduction in
the use of tobacco, smoking still causes more deaths glo-
bally than diseases like tuberculosis, HIV and malaria
combined, making it the largest preventable health risk
factor [3, 4]. The use of tobacco is legally allowed and
therefore the prevalence of smoking behaviour is still
very high. While in the developed countries tobacco use
is reduced and restricted, in developing countries the to-
bacco epidemic is still in the growing phase [1, 5]. It has
been estimated that tobacco smoking causes globally 6
million deaths in a year [6]. 80% of these deaths are* Correspondence: sulev.koks@ut.ee
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all makes tobacco smoking the largest single avoidable
cause for mortality. Reducing the prevalence of smoking
increases the health of the general population by avoid-
ing premature disability and death. Smoking cessation
and support to stop smoking are the easiest tools to
improve the quality of life in population [7, 8].
While it is clear that smoking increases mortality, the
association between smoking and mortality is different
across specific causes of death. Cancers, chronic
obstructive diseases of respiratory system and cardiovas-
cular diseases are the most commonly referred smoking-
induced causes of death.
The association between smoking and lung cancer has
been described already in 1950 and following years [9–12].
Later studies found clear association with other cancers as
well [13]. Tobacco smoking is known to cause cancers of
upper gastrointestinal tract, pancreas, prostate [14]. Whilele is distributed under the terms of the Creative Commons Attribution 4.0
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tract cancers, the connection between smoking and other
cancers does not have conclusive evidence.
Tobacco smoking is reported to cause 90% of all
chronic obstructive pulmonary disease (COPD) mortality
and smoking cessation is the best measure to avoid this
outcome [15]. The relative risk for smokers to die from
COPD is 25.6 in men and 22.3 in women, compared to
non-smokers [16]. Therefore, one of the most common
health problems in smokers is COPD [16, 17]. The de-
velopment of COPD is dependent on the chronic per-
sistent inflammation in the lung tissue that induces
tissue-remodelling [18]. COPD is the most common and
the most prevalent disease in smokers and smokers have
very highly increased risk for COPD.
Cardiovascular diseases have been found to be the
third major cause of death caused by smoking [16, 19].
The main causes for death are ischaemic heart disease,
cerebrovascular disease and other heart diseases [16].
Interestingly the risks caused by smoking of death due
coronary heart disease are remarkably different between
men and women [20]. Women who smoke have four
times increased risk of death from ischaemic heart dis-
ease, while male smokers only have twofold increased
risk [20]. For cerebrovascular diseases, this sex difference
in risk has not been found [21]. This influence of sex on
the risk of ischaemic heart disease is striking and its
mechanism could be biological or behavioural.
Increased prevalence of chronic diseases suggests in-
creased inflammatory activity in smokers. Indeed, several
studies indicate chronic inflammation in the smokers
and different immunomodulating toxins in the smoke
probably cause increased immune reactivity [22, 23]. A
recent study analysed RNA expression profiles in the
blood of smokers and non-smokers and identified a
highly significant increase in the expression of GPR15
gene [24]. GPR15 is an orphan receptor that is respon-
sible for the homing of tissue-specific immune cells [25].
Several previous studies have shown that the associ-
ation between smoking with different causes of deaths
is variable [26]. There are some large-scale population
studies where causes of death and association with
smoking have been addressed [7, 13, 16]. However,
more detailed differential risk analyses for smoking
and causes of death are not that common [27]. The
goal of present study was to analyse the smoking-
caused mortality in the Estonian Genome Center
cohort and to describe the differential sensitivity for
the different specific causes of death.
Methods
The aim, design and setting of the study
The aim of the study was to analyse smoking-induced
mortality profile in Estonia using data at the EstonianGenome Center. Estonian Genome Center at the
University of Tartu is a population-based biobank that
recruited a cohort of 51,756 participants, including
adults from all counties in Estonia, accounting for ap-
proximately 5% of the Estonian adult population during
the recruitment period. Recruitment was performed dur-
ing the period from 2002 to 2012 [28]. At baseline, an
extensive phenotype questionnaire was conducted to-
gether with a measurement panel. Follow-up data is
available from linkage with national health-related regis-
tries and the Estonian Health Insurance database.
Mortality information was retrieved from the Estonian
Causes of Death Registry and last retrieval was per-
formed in September 2015.
The Ethics Review Committee on Human Research of
the University of Tartu approved the protocols and
informed-consent forms used in this study. All of the
participants signed a written informed-consent form.
Smoking data
Smoking data were collected during the recruitment of
donors to the Estonian Genome Center. The following
questions were asked:
1) “If you have ever smoked regularly, when did you
start?”
2) “How many of the tobacco products have you used
during the last 12 months?”
3) “For how many years have you used tobacco
products with this amount?”
4) “What is the amount of tobacco products you used
most commonly?”
5) “For how many years you have used tobacco
products as described?”
Smoking behaviour was divided into three major cat-
egories: current smokers, former smokers and never
smoked. Former smokers were individuals who had not
smoked for at least one year prior to recruitment.
Statistical analysis
All statistical analyses were stratified by sex, as previous
analysis indicated significant differences in the smoking
patterns between males and females. Statistical analysis
was performed in R studio and packages “survival”, “epi-
tools”, “Publish”, “dplyr” were used. Survival data were
modelled by using Cox model [29]. Survival was calcu-
lated from the date when subjects joined the Estonian
Genome Centre cohort (2002–2012) and censored at
date of death, retrieved from the National Death
Registry, or September 2015, whichever came first.
The data on smoking status, smoking intensity and
smoking pattern was categorized (current, former and
never smokers; smoking up to 10, 10–20 or more than
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20 years of smoking history) and tabulated by four age
groups (18–25, 26–45, 46–65 and more than 65 years).
Mortality data was tabulated according to the cause of
death, smoking status and sex of all participants. For
survival analysis, the Kaplan-Meier estimator was used
to plot survival curves. Starting time-point was the date
when subjects joined the Estonian Genome Centre
cohort and the end-point was the date of data retrieval
from the National Death Registry. Cox proportional
hazards regression analysis was used to calculate hazard
ratio for all-cause mortality and cause-specific mortality,
comparing current and former smokers with never-
smokers, using age as a time scale (to account for left-
truncation in the data). Cox regression was also used to
estimate the effects of smoking intensity (cigarettes per
day) and length of smoking history on overall survival.
Using the Kaplan-Meier method for left-truncated data,
the median survival time for current, former and never
smokers in the cohort also was estimated with a 95%
confidence interval.
For cause-specific mortality, the causes of death
according to the 10th Revision of International Statistical
Classification of Diseases and Related Health Problems
(ICD-10) were analysed separately in men and women.
Results
General smoking characteristics in the cohort
The Estonian Genome Center includes 51,756 partici-
pants: 17,777 men and 33,979 women (Table 1), aged 18
and over at recruitment. The recruitment period was
between 2002 and 2012.
Basic demographic information and smoking charac-
teristics are given in the Tables 2 and 3. Of all 17,777
men (Table 2), 39.4% were never-smokers, 20.8% former
and 39.8% current smokers. Of all 33,979 women
(Table 3), 67.3% were never-smokers, 10.0% former
and 22.7% current smokers. This indicates clearly
higher prevalence of smoking in Estonian men than
women. The proportion of smokers in the cohort is
similar to that of the general Estonian population [1].Table 1 Age distribution in the cohort of the Estonian Genome
Center of the University of Tartu 2002–2012
Men Women Total
Variable n % n % n %
Age group
18–25 3896 7.5 5302 10.3 9198 17.8
26–45 6016 11.6 12,436 24.0 18,452 35.6
46–65 5292 10.2 11,257 21.8 16,549 32.0
over 65 2573 5.0 4984 9.6 7557 14.6
Total 17,777 34.3 33,979 66.7 51,756 100.0According to the recent WHO data, the smoking
prevalence in Estonian men is 41.2% and in women
24.9% [1].
The average age to start smoking in men was 18 (SD
4.2) years and in women 21 (SD 6.3) years. Analysis of
the different age groups indicated that nowadays people
start smoking at a younger age than in the past. Men in
the age group 65+ had started smoking at age 20 and
women at age 27 in the average. On the other hand,
average age of starting to smoke in the youngest age
group (18–25) was 16 for both, men and women.
The cohort was divided into two groups according to
the duration of smoking – up to 20 years and over
20 years of smoking. In the study cohort, most of the
smokers were smoking for less than 20 years. This trend
also was valid in all subgroups of the cohort.
The number of cigarettes per day differed significantly
between male and female smokers. On average, men
smoked 15 (SD 9) and women smoked 9 (SD 7) ciga-
rettes per day. The average number of cigarettes per day
was similar in current and former smokers.
All-cause mortality
By September 2015, 3364 (1649 men and 1715 women)
people the cohort had died. The average age at death
was 69 (SD 14) and 74 (SD 14) years for men and
women, respectively. A general description of the more
frequent causes of death and their association with
smoking is given in the Table 4.
The Kaplan-Meier curves for overall survival were sig-
nificantly different in current, former and never
smokers, in both men and women (Fig. 1). The test for
survival curve differences in men between three different
smoking categories (“Never”, “Former”, “Current”) was
highly significant (p = 1.8*10−40). In case of women, the
difference was also highly significant (p = 1.3*10−14) for
three-group comparison. The never smoked group had
the longest survival and current smokers had the short-
est survival. Survival of former smokers was in-between
the never and current smokers indicating beneficial
effect of quitting.
Age-adjusted Cox regression of all-cause mortality in
both sexes indicated significantly increased hazard ratio
(HR) and 95% confidence interval (CI), for current 3.1
(CI 2.8–3.4) and former 1.6 (CI 1.5–1.8) smokers, com-
pared to never smokers. When different sexes were ana-
lysed separately, almost similar results were seen. In
male current smokers HR was 2.5 (CI 2.2–2.8) and in
former smokers 1.3 (CI 1.2–1.5) for all-cause mortality.
Currently smoking women had HR 2.6 (CI 2.2–3.0) and
former smokers had 1.3 (CI 1.1–1.5) for all-cause mor-
tality. Taken together, smoking status was significantly
associated with increased all-cause mortality and this
association was similar for men and women.
Table 2 Smoking characteristics by age-group in the male cohort of the Estonian Genome Center of the University of Tartu 2002–2012
Age group
18–25 26–45 46–65 Over 65 Total
Variable n % n % n % n % n %
Smoking status
Total 3896 100.0 6016 100.0 5292 100.0 2573 100.0 17,777 100.0
Never smoker 1854 47.6 2281 37.9 1783 33.7 1093 42.5 7011 39.4
Former smoker 218 5.6 1013 16.8 1409 26.6 1058 41.1 3698 20.8
Current smoker 1824 46.8 2722 45.3 2100 39.7 422 16.4 7068 39.8
Age at start (SD) 16 (2.4) 18 (3.5) 19 (4.5) 20 (5.4) 18 (4.2)
Current smokers
Years smoked (SD) 5 (2.8) 17 (6.5) 35 (7.1) 51 (8.0) 108 (14.7)
Up to 20 years 1773 100.0 1772 66.8 52 2.5 4 0.9 3601 52.3
Over 20 years 0 0.0 879 33.2 1991 97.5 409 99.1 3279 47.7
Cigarettes per day
Number of persons 1807 100.0 2698 100.0 2084 100.0 419 100.0 7008 100.0
Up to 10 634 35.1 551 20.4 299 14.4 102 24.3 1586 22.6
10–20 1101 60.9 1898 70.4 1555 74.6 295 70.4 4849 69.2
Over 20 72 4.0 249 9.2 230 11.0 22 5.3 572 8.2
Former smokers
Years smoked (SD) 4 (2.6) 11 (6.5) 22 (11.3) 29 (15.2) 20 (13.7)
Up to 20 years 192 100.0 893 91.2 645 47.1 340 33.0 2070 58.0
Over 20 years 0 0.0 86 8.8 724 52.9 691 67.0 1501 42.0
Cigarettes per day
Number of persons 163 100.0 766 100.0 1095 100.0 869 100.0 2893 100.0
Up to 10 87 53.4 184 24.0 161 14.7 126 14.5 558 19.3
10–20 72 44.2 515 67.2 791 72.3 661 76.1 2039 70.5
Over 20 4 2.4 67 8.8 143 13.0 82 9.4 296 10.2
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Smoking significantly reduced median age of death. In
the entire study group, median age of death in never
smokers was 85.7 (CI 85.4–86.2), in former smokers
80.6 (CI 79.6–81.6) and in current smokers 74.7 (CI
73.5–75.7) years.
The median age of death for men who never smoked was
82.6 (CI 81.4–83.6), for former smokers 78.4 (CI 77.1–79.4)
and for current smokers 71.2 (CI 70.2–72.3) years. Median
age of death for women who never smoked was 86.4 (CI
86.1–86.8), for former smokers 85.8 (CI 83.4–88.1) and for
current smokers 80.6 (CI 77.9–81.8) years.
Therefore, we estimate that the median loss of life
years in smoking men is 11.4 years and in women
5.8 years at lost. In the case of men, former smokers
lived significantly longer than current smokers, but sig-
nificantly less than never smokers. In the case of women,
the difference in age of death of former and never
smokers were very small.Effect of smoking duration and smoking intensity on all-
cause mortality
The increased risk for all-cause mortality was also sig-
nificantly associated with smoking duration. Men who
smoked more than 20 years had HR 2.1 (CI 1.9–2.3) and
men who smoked less than 20 years had HR 2.3 (CI
2.1–2.5). Women with smoking duration more than
20 years had HR 2.7 (CI 2.4–3.1) and with less than
20 years had HR 1.4 (CI 1.3–1.6). However, the number
of cigarettes per day had a less severe influence on the
all-cause mortality than smoking duration.
Cause-specific mortality
The subsequent analysis involved specific causes for
mortality. The study cohort altogether had 272 unique
ICD-10 main categories as cause of death. The most fre-
quent causes of death (more than 100 cases) were
chronic ischaemic heart disease (I25), hypertensive heart
disease (I11), malignant neoplasm of bronchus and lung
Table 3 Smoking characteristics by age-group in the female cohort of the Estonian Genome Center of the University of Tartu 2002–2012
Age group
18–25 26–45 46–65 Over 65 Total
Variable n % n % n % n % n %
Smoking status
Total 5302 100.0 12,436 100.0 11,257 100.0 4984 100.0 33,979 100.0
Never smoker 3390 63.9 7587 61.0 7471 66.4 4407 88.4 22,855 67.3
Former smoker 328 6.2 1374 11.0 1334 11.8 366 7.3 3402 10.0
Current smoker 1584 29.9 3475 28.0 2452 21.8 211 4.3 7722 22.7
Age at start (SD) 16 (2.2) 20 (4.4) 23 (7.3) 27 (10.0) 21 (6.3)
Current smokers
Years smoked (SD) 5 (2.7) 16 (6.2) 29 (8.3) 42 (11.0) 92 (11.7)
Up to 20 years 1540 100.0 2556 76.4 314 13.1 10 4.8 4420
Over 20 years 0 0.0 790 23.6 2076 86.9 197 95.2 3063
Cigarettes per day
Number of persons 1570 100.0 3435 100.0 2436 100.0 211 100.0 7652 100.0
Up to 10 968 61.7 1510 44.0 1020 41.9 104 49.3 3602 47.0
10–20 584 37.2 1842 53.6 1363 55.9 104 49.3 3893 51.0
Over 20 18 1.1 83 2.4 53 2.2 3 1.4 157 2.0
Former smokers
Years smoked (SD) 3 (2.4) 9 (6.1) 18 (10.7) 24 (14.9) 14 (10.9)
Up to 20 years 293 100.0 1210 94.7 768 60.9 162 45.6 2433 76.3
Over 20 years 0 0.0 68 5.3 494 39.1 193 54.4 755 23.7
Cigarettes per day
Number of persons 259 100.0 1051 100.0 1049 100.0 300 100.0 2659 100.0
Up to 10 183 70.6 573 54.5 571 54.4 160 53.3 1487 55.9
10–20 75 29.0 470 44.7 458 43.7 136 45.3 1139 42.9
Over 20 1 0.4 8 0.8 20 1.9 4 1.4 33 1.2
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hort (Table 4). Men and women also were analysed sep-
arately and for specific causes of death age-adjusted
hazard ratio was calculated with non-smokers as
reference. Statistically significant findings are shown in
Tables 5 and 6.
The most significant specific causes for mortality in
currently smoking men were malignant neoplasm of
bronchus and lung (C34, HR 32.9), heart failure (I50,
HR 24.4), chronic obstructive pulmonary disease (J44,
HR 23.1) and subsequent myocardial infarction (I22,
HR 9.4) (Table 5, Fig. 2). Current smokers also had a
significantly increased hazard ratio to die from malig-
nant neoplasms at unspecified sites (C80, HR 7.8).
Interestingly, current smokers also had a significantly
elevated hazard ratio for accidental poisoning by an
exposure to alcohol (X45, HR 3.6), for cerebral infarc-
tion (I63, HR 3.3), for hypertensive heart disease (I11,HR 2.1) and chronic ischaemic disease (I25, HR 1.9)
as causes of death.
Compared to current smokers, former male smokers
(Table 5) had significantly lower hazard ratio values for
most of the causes of death. This finding illustrates a
clear health benefit of quitting smoking as the general
risk for death reduced from 2.5 to 1.3 and the number
of specific causes for death decreased. In men who
stopped smoking, only four causes of death remained
statistically significant compared to those who have
never smoked. These causes of death were chronic ob-
structive pulmonary disease (J44, HR 9.7), malignant
neoplasm of bronchus and lung (C34, HR 9.2), subse-
quent myocardial infraction (I22, HR 5.4) and cerebral
infarction (I63, HR 2.7).
In the case of currently smoking women (Table 6, Fig. 3)
the highest hazard ratio as a cause of death were for
chronic obstructive pulmonary disease (J44, HR 19.3), for
Table 4 Basic characteristics of smoking, number of all causes of death and the most common cause-specific deaths in the studied
cohort
Variable Men Women
Smoking status Current Former Never Current Former Never
n n n n n n
Persons in cohort 7068 3698 7011 7722 3402 22,855
All causes death in cohort 627 548 474 270 147 1298
C16 Malignant neoplasm of stomach 8 13 10 10 5 34
C18 Malignant neoplasm of colon 3 10 9 4 1 25
C25 Malignant neoplasm of pancreas 11 18 11 12 6 32
C34 Malignant neoplasm of bronchus and lung 73 42 5 15 6 19
C50 Malignant neoplasm of breast – – – 12 8 35
C56 Malignant neoplasm of ovary – – – 5 8 25
C61 Malignant neoplasm of prostate 16 17 29 – – –
C80 Malignant neoplasm without specification of site 9 – 2 4 – 9
I11 Hypertensive heart disease 41 41 39 20 22 190
I13 Hypertensive heart and renal disease 8 10 13 5 4 28
I21 Acute myocardial infarction 16 11 12 6 4 31
I22 Subsequent myocardial infarction 12 9 2 2 2 11
I25 Chronic ischaemic heart disease 80 113 100 21 21 243
I35 Nonrheumatic aortic valve disorders 5 2 6 1 1 17
I42 Cardiomyopathy 16 9 12 5 2 11
I50 Heart failure 10 2 1 4 1 17
I63 Cerebral infarction 16 30 13 9 9 79
I70 Atherosclerosis 2 3 5 2 1 11
J15 Bacterial pneumonia 1 4 3 3 2 7
J44 Chronic obstructive pulmonary disease 17 18 2 7 1 10
K70 Alcoholic liver disease 8 7 6 7 0 2
R99 Ill-defined and unspecified causes of mortality 6 3 4 5 0 2
X45 Accidental poisoning by and exposure to alcohol 14 1 3 2 0 1
X70 Intentional self-harm by hanging, strangulation and suffocation 13 3 8 5 1 5
Fig. 1 Kaplan-Meier survival probabilities for current and former smokers and for men and women who have never smoked. Reduced survival of
the smokers is evident
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Table 5 Smoking related adjusted hazard ratio (HR) and 95% confidence intervals (CI 95%) for the statistically significant cause-specific
mortality in men
Variable Current smokers Former smokers
ICD-10 code for cause of death HR CI 95% HR CI 95%
C34 Malignant neoplasm of bronchus and lung 32.9 13.2–82.0 9.2 3.7–23.4
C80 Malignant neoplasm without specification of site 7.8 1.5–39.5 – –
C16–C80 Malignant neoplasms 4.0 2.1–5.4 1.7 1.2–2.3
I11 Hypertensive heart disease 2.1 1.3–3.3 1.2 0.8–1.8
I22 Subsequent myocardial infarction 9.4 2.0–43.3 5.4 1.2–24.8
I25 Chronic ischaemic heart disease 1.9 1.4–2.6 1.3 0.9–1.7
I50 Heart failure 24.4 2.8–213.1 2.1 0.2–23.4
I63 Cerebral infarction 3.3 1.5–7.0 2.7 1.4–5.3
I00–I99 Diseases of the circulatory system 2.6 1.8–2.7 1.3 1.1–1.5
J44 Chronic obstructive pulmonary disease 23.1 5.2–101.8 9.7 2.3–41.7
J00–J99 Diseases of the respiratory system 7.8 3.2–18.7 4.2 1.8–9.7
X45 Accidental poisoning by and exposure to alcohol 3.6 1.1–12.7 0.5 0.05–5.1
V01–Y98 External causes of morbidity and mortality 2.2 1.5–3.3 0.8 0.5–1.4
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(I50, HR 10.3) and for atherosclerosis (I70, HR 10.2).
Current smokers also had increased hazard ratio for ill-
defined and unspecified causes of mortality (R99, HR 8.5),
for malignant neoplasm of bronchus and lung (C34, HRTable 6 Smoking related adjusted hazard ratio (HR) and 95% confiden
mortality in women
Variable
ICD-10 code for cause of death
C25 Malignant neoplasm of pancreas
C34 Malignant neoplasm of bronchus and lung
C56 Malignant neoplasm of ovary
C16–C80 Malignant neoplasms
I11 Hypertensive heart disease
I13 Hypertensive heart and renal disease
I21 Acute myocardial infarction
I25 Chronic ischaemic heart disease
I50 Heart failure
I63 Cerebral infarction
I70 Atherosclerosis
I00–I99 Diseases of the circulatory system
J15 Bacterial pneumonia
J44 Chronic obstructive pulmonary disease
J00–J99 Diseases of the respiratory system
K70 Alcoholic liver disease
R99 Ill-defined and unspecified causes of mortality
X70 Intentional self-harm by hanging, strangulation and suffoc
V01–Y98 External causes of morbidity and mortality6.7), for bacterial pneumonia (J15, HR 6.4), for acute myo-
cardial infarction (I21, HR 4.7) and intentional self-harm
by hanging, strangulation and suffocation (X70, HR 4.6) as
a cause of death. In currently smoking women, the hazard
ratio for accidental poisoning by an exposure to alcoholce intervals (CI 95%) for the statistically significant cause-specific
Current smokers Former smokers
HR CI 95% HR CI 95%
4.0 1.9–8.3 1.9 0.8–4.7
6.7 3.2–14.4 3.0 1.2–7.6
0.9 0.3–2.5 2.4 1.1–5.3
2.7 1.9–3.7 1.8 1.2–2.6
2.2 1.3–3.6 1.4 0.9–2.2
3.3 1.1–9.8 1.7 0.6–4.9
4.7 1.9–12.2 1.6 0.6–4.6
2.1 1.3–3.3 1.1 0.7–1.7
10.3 2.9–35.8 0.9 0.1–6.6
3.4 1.6–7.0 1.6 0.8–3.1
10.2 1.8–57.4 1.2 0.2–9.6
2.7 2.1–3.5 1.3 1.0–1.7
6.4 1.3–32.2 3.2 0.7–15.8
19.3 7.1–52.6 1.3 0.2–10.2
12.0 5.3–27.3 1.8 0.5–6.1
13.9 2.6–75.8 – –
8.5 1.6–45.6 – –
ation 4.6 1.2–18.1 1.6 0.2–13.7
7.6 3.9–14.7 2.6 1.0–6.5
Fig. 2 Forest plot of the hazard ratio (HR) for specific causes of
death illustrates the profile of the major causes of death in currently
smoking men. Age-adjusted Cox regression modelling was applied
Kõks et al. BMC Public Health  (2018) 18:34 Page 8 of 11(X45) was elevated, but this increase did not reach statis-
tical significance.
Smoking cessation significantly reduced the risks for
specific causes of death and most of the hazard ratios
were not different compared to the never smoked group
(Table 6). In former smokers only malignant neoplasm
of the bronchus and lung (C34, HR 3.0) and malignantFig. 3 Forest plot of the hazard ratio (HR) for specific causes of death
illustrates the profile of the major causes of death in currently smoking
women. Age-adjusted Cox regression modelling was appliedneoplasm of the ovaries (C56, HR 2.4) remained
significant specific causes of death.
Taken together, current smokers have significantly in-
creased mortality and a specific pattern of cause of
death. Respiratory and cardiovascular diseases were the
most significant causes of death. This indicates, that
smoking does the most harm to the lungs and cardiovas-
cular system. The former smokers group had signifi-
cantly less mortality than current smokers and therefore,
smoking cessation significantly reduces the hazard ratio
for cause-specific mortality. Former smokers still have
significantly increased hazard to die from the lung
diseases.
Discussion
Based on the epidemiological analysis of tobacco smok-
ing in the cohort of the Estonian Genome Center, this
study concluded that Estonia still belongs to the group
of countries with high number of smokers. On average,
there are two times more smokers in Estonia than in
Western-European countries. The high number of
smokers also is characteristic for other Eastern-
European countries. This statement is particularly true
in men. In Estonia and other Eastern-European coun-
tries around 40% of men are smokers, whereas in
Western-European countries only 10–20% of men are
smokers. In the case of female smokers, Estonia is simi-
lar to Western-European countries, where 20% of
women smoke [1]. This fits the typical epidemiologic
pattern seen in Europe and developed countries.
Differences between different countries are smaller in
case of women and are prominent in the case of men.
These differences also explain the significantly worse
health of men in Eastern-European countries. Men
smoke too much and they pay for that with their health
and quality of life as seen by the reduced life span.
The smoking prevalence in the Estonian Genome
Center cohort is similar to the prevalence described in
other study based on general population in three Baltic
states [30]. In addition, the age-group prevalence of the
Estonian Genome Center cohort is similar to the general
Estonian population [28]. Therefore, our results are
generalizable for the entire Estonian population.
While the proportion of smokers in Estonia has been
stable for 20 years, the age at which individuals start
smoking tobacco has decreased remarkably. At present,
people start to smoke at the median age of 16 and this is
similar for men and women. This trend is worrisome
and has an important impact on the health of the
Estonian population.
The age-group analysis indicated that men start to quit
smoking at the age 46–65, women start quitting 26–45.
This indicates that women smoke for a shorter period of
their life. Taken together, men start smoking earlier, they
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day) and they quit smoking later. At the same time,
women smoke less (mostly 10 cigarettes per day) they start
smoking later and give up smoking earlier. This difference
could also be detectable as the difference in survival and
causes of death. Therefore smoking has a significantly
larger impact on men’s health than in women.
There present study analysed the impact of tobacco
smoking on the hazard of all-cause and cause-specific
mortality. Survival analysis clearly indicated shorter me-
dian survival in smokers compared to non-smokers.
Survival analysis also indicated that smoking cessation is
beneficial for the survival. This means that toxic effects
of smoking are reversible. The positive effect of quitting
on the survival has been described in many previous
studies [16, 17, 19].
Interestingly, in women the general survival differ-
ences caused by tobacco smoking were less prominent.
For example, men who smoked lived on average
11.4 years less than non-smokers, bud women who
smoked only lost 5.8 years on average. In some previous
studies, similar sex-differences in smoking effects have
been found [31]. This sex-difference may be explained
by the lower smoking activity in women. In our sample
women smoked 9 cigarettes per day while men smoked
15 cigarettes per day on average. Women also start
smoking later and quit earlier that makes their smoking
duration shorter and this explains the reduced number
of cigarettes smoked by women. Previous studies
support this idea. If women smoke more they have
mortality and morbidity profile similar to men and the
sex differences disappear [32, 33].
The loss of years found from the survival analysis in
the present study was similar to the findings from previ-
ous studies where loss of at least 10 years was found
[17]. This indicates that the study design used and the
results are comparable with other studies. For example,
the study of Jha et al. analysed survival from the age 25
[17]. The present study included people from the age 18
and mortality data were retrieved from the National
Death Registry. This approach has been used for many
previous studies.
The impact of smoking duration on general mortality
gave somewhat controversial results as in men we found
increased mortality in both groups compared to non-
smokers. In case of men, the difference in general mor-
tality between smoking more than 20 years and less than
20 years was very small (HR 2.1 versus 2.3) and statisti-
cally not significant. In case of women, the difference
related to smoking duration was significant. Women
smoking more than 20 years had HR 2.7 (CI 2.4–3.1)
and women smoking less than 20 years have HR 1.4 (CI
1.3–1.6). This finding is similar to the previously
published findings [34]. Similarly, we found that numberof cigarettes per day does not have impact on the
all-cause mortality.
The cause-specific analysis of death should describe
the most common reasons why smokers lose years of
their life. The comparison of causes of death induced by
smoking in men and women identified very high similar-
ities between both sexes in the pattern of cause of death.
Namely, the most significantly smoking-associated
causes of death were diseases of the respiratory and
cardiovascular systems both in men and women. This
indicates that there is a common biological mechanism
behind the smoking that increases morbidity and mor-
tality. This mechanism is the same in men and women.
One very good candidate for this common pathway is
the GPR15 that was recently found to be upregulated in
both male and female smokers [24].
In addition to the lung and heart diseases, the one of
the largest hazard ratio was related to external causes of
death. In men, this cause was death from accidental poi-
soning by an exposure to alcohol (X45). In women, these
causes were alcoholic liver disease (K70) and intentional
self-harm by hanging, strangulation, suffocation (X70).
Alcoholic liver disease (K70) is closely related to a poi-
soning by an exposure to alcohol (X45) and should be
taken as an external cause of disease. The significantly
increased risks for external causes of death have been
described in few previous studies and more detailed ana-
lysis is difficult to find [14]. The prevalence of alcohol
poisoning and self-harm in former smokers as causes of
death were the same in former smoker and non-
smokers. This means that the increased incidence of sui-
cide and alcohol intoxication in current smokers could
reflect particular biologically determined behavioural
endophentoype and personality characteristics of current
smokers. Smokers could be more impulsive or more
prone to risk taking. One side of this behaviour is
increased alcohol consumption, binge drinking and sui-
cide. Not many studies indicate causes for this kind of
association, but most probably there is common genetic
variation between smokers and suicide victims. One
recent study found an association between the
polymorphic variable number tandem repeat (VNTR) in
the SLC6A4 gene and increased risk for tobacco use dis-
order [35]. The association between polymorphisms in
the BDNF gene and nicotine dependence also has been
described [36]. Moreover, as tobacco smoking behaviour
is often explained in conjunction with mood disorders,
the link between suicide and smoking is not that surpris-
ing. At least one deletion in the GSTM1 and GSTT1
genes has been described in anxious smokers while no
association with mood disorders have been found [37].
One of the limitations of the study is the small number
of several specific causes of death that could make our
analysis imprecise. This small number is caused by the
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get better estimations and this study can be a starting
point for the repeated mortality analysis of the Estonian
Genome Center cohort. Extended observation will
eventually increase the number of specific causes and
improve the precision of the analysis. In order to
improve the regression analysis, we merged some cases
(like J44, J45 and J47) that increased the power to esti-
mate proportional hazard for smokers and ex-smokers.
This helped to get more reliable HR estimations.
Conclusions
In conclusion, the prevalence of tobacco smoking is still
high in Estonia and men smoke at least two times more
than women. This high prevalence is reflected in sub-
stantial loss of years of life and shorter survival of men.
Smoking cessation can reverse the increased mortality,
but the time needed for this reversal is not known. The
two main types of cause of death in smokers were dis-
eases of lung and cardiovascular system. The third group
of cause of death is self-destructive behaviour. This find-
ing suggests a common biological substrate in the brain
of nicotine addicts and risk-taking behaviour. Better
knowledge about the link between psychiatric illnesses
and smoking could help to develop more effective inter-
ventions. Further studies are required to understand the
genetic and biological background of this association.
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